A new study by University of Utah may proffer an innovative drug for the treatment of diabetes, a chronic disease with over 20 million Americans as its patients.
March 28, 2007 (Press Release) --
The study by University of Utah was conducted on mice and rats that develop diseases similar to diabetes. The study showed that obstructing the formation of a fat molecule, called ceramide, helped check insulin resistance. Ceramide is connected to saturated fats, stated Scott Summers, Ph.D., Associate Professor of internal medicine and one of the authors of the study, in a statement reported on March 7, 2007 by The Salt Lake Tribune.
The findings may give new ways of treating or even preventing the type 2 diabetes. Also, to an extent, it has the potential to treat type 1 diabetes also, something researchers have a grant to look into, said Summers.
He added, “If we pre-treated with this drug, [the animals] never became diabetic”. This kind of treatment would be for people suffering from type 2 diabetes, the most common diabetes form, said Summers.
According William Holland, the lead author of the study, on March 7, 2007, said in a statement reported by The Salt Lake Tribune, that some existing drug treatments make the body more susceptible to the quantum of the insulin produced naturally in the body. But the findings of the University of Utah proffer another way to treat the insulin resistance.
“We show that preventing ceramide accumulation in a number of different [mouse and rat] models . . . will improve insulin sensitivity”, added Holland.
The drugs tested on animal models may cause severe side effects in human beings. So pharmaceutical firms will have to look for new methods to target ceramide molecule in patients. It could take a long time of 10 years before a suitable human drug passes through the stage of clinical trials.
The RNCOS report “New Developments in Insulin Delivery System (2006)” projects the diabetes drugs and equipment market to go beyond US$ 20 Billion by 2010. This segment continues to see radical development in research for both technologies and therapeutic compounds in drug delivery.
The market research report provides an insight into the global diabetes drug market. It highlights the worldwide trends in insulin supply and demand, insulin delivery market, various diabetes treatments (including gene therapy, pump therapy, and Xenotransplantation), key drivers, and future outlook of the market.
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
For more information visit: http://www.rncos.com/Report/IM040.htm
Current Industry News: http://www.rncos.com/blog
The findings may give new ways of treating or even preventing the type 2 diabetes. Also, to an extent, it has the potential to treat type 1 diabetes also, something researchers have a grant to look into, said Summers.
He added, “If we pre-treated with this drug, [the animals] never became diabetic”. This kind of treatment would be for people suffering from type 2 diabetes, the most common diabetes form, said Summers.
According William Holland, the lead author of the study, on March 7, 2007, said in a statement reported by The Salt Lake Tribune, that some existing drug treatments make the body more susceptible to the quantum of the insulin produced naturally in the body. But the findings of the University of Utah proffer another way to treat the insulin resistance.
“We show that preventing ceramide accumulation in a number of different [mouse and rat] models . . . will improve insulin sensitivity”, added Holland.
The drugs tested on animal models may cause severe side effects in human beings. So pharmaceutical firms will have to look for new methods to target ceramide molecule in patients. It could take a long time of 10 years before a suitable human drug passes through the stage of clinical trials.
The RNCOS report “New Developments in Insulin Delivery System (2006)” projects the diabetes drugs and equipment market to go beyond US$ 20 Billion by 2010. This segment continues to see radical development in research for both technologies and therapeutic compounds in drug delivery.
The market research report provides an insight into the global diabetes drug market. It highlights the worldwide trends in insulin supply and demand, insulin delivery market, various diabetes treatments (including gene therapy, pump therapy, and Xenotransplantation), key drivers, and future outlook of the market.
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
For more information visit: http://www.rncos.com/Report/IM040.htm
Current Industry News: http://www.rncos.com/blog
Email
Print
SPAM
